Iniparib: Development discontinued

Sanofi discontinued development of iniparib after reporting top-line data from a Phase III trial in non-small cell lung cancer (NSCLC) and a Phase II trial in ovarian cancer. In the open-label, international Phase III ECLIPSE trial in 780 patients with previously untreated metastatic stage IV squamous NSCLC, iniparib plus gemcitabine and carboplatin missed the primary endpoint of improving overall survival (OS) vs. carboplatin and gemcitabine alone. Additionally, the pharma said that top-line data from a Phase II trial in patients with platinum-resistant ovarian cancer "do not support further development of iniparib in this patient population." Sanofi said it will record a $285 million charge for the discontinuation. ...